Advertisement

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Peter Clark, MA, MD, FRCP: A Payer Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Dec
14
Today In Oncology
Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer
Mobile Health Intervention Offers Tailored Support for Adolescent and Young Adult Breast Cancer Survivors
Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer
Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML
Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo